105 DIGITAL DRIVE, NOVATO, CA
To Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Pipeline
Amended material disclosure
Material disclosure
Reports First Quarter 2026 Financial and Operating Results
Completes Acquisition of Amicus Therapeutics
Other Events
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Tender Offer Statement by Third Party
Correspondence